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Clinical observations associated with proven
and unproven cases in the ESCRS study
of prophylaxis of postoperative
endophthalmitis after cataract surgery
Peter Barry, FRCS, SusanneGardner, DPharm,David Seal,MD,GeorgeGettinby,DPhil, Fiona Lees,MSc,
Magnus Peterson, MSc, Crawford Revie, PhD, for the ESCRS Endophthalmitis Study Group
PURPOSE: To describe cases of postoperative endophthalmitis in the European Society of Cataract
& Refractive Surgeons (ESCRS) study of the prophylaxis of endophthalmitis, compare characteris-
tics of unproven cases and cases proven by culture or polymerase chain reaction, and compare the
characteristics with those in other reported series.
SETTING: Twenty-four ophthalmology units in Austria, Belgium, Germany, Italy, Poland, Portugal,
Spain, Turkey, and the United Kingdom.
METHODS: Univariable and multivariable logistic regression models were used to analyze data for
statistical association of signs and symptoms in cases with proven or unproven endophthalmitis.
Specific data describing characteristics of the cases were compared between the 2 types of cases.
RESULTS: Data from 29 endophthalmitis cases were analyzed. Swollen lids and pain were statisti-
cally associated with proven cases of endophthalmitis on univariable regression analysis. Multivari-
able analysis indicated that swollen lids and an opaque vitreous were associated with proven cases.
Five cases of endophthalmitis occurred in the cefuroxime-treated groups. No case of streptococcal
infection occurred in the cefuroxime-treated groups. However, cases of infection due to strepto-
cocci showed striking differences in visual acuity and were associated with earlier onset. Character-
istics in the 29 cases parallel results in previous studies, such as the Endophthalmitis Vitrectomy
Study, although the addition of a control group in the ESCRS study elicited additional findings.
CONCLUSION: Swollen lids, pain, and an opaque vitreous were statistically associated with proven
endophthalmitis cases in the ESCRS study.
The results and rationale for the European Society of
Cataract & Refractive Surgeons (ESCRS) study of the
prophylaxis of endophthalmitis after cataract surgery
have been presented,1–3 as has a description of the
microbiologic and molecular methods used.4 Intra-
cameral injection of 1 mg cefuroxime in the 2 cefurox-
ime-treated groups resulted in a nearly 5-fold
reduction in the rates of postoperative endophthalmi-
tis over rates in study groups that did not receive the
intracameral injection.1 We present characteristics of
each case of endophthalmitis in the study and compare
the signs and symptoms in proven cases and unproven
cases.
PATIENTS AND METHODS
Data from the cases of endophthalmitis in the ESCRS study
of the prophylaxis of endophthalmitis after cataract surgery
were reviewed for comparison of clinical characteristics.
The clinical signs and symptoms in cases of proven en
dophthalmitis were compared with those in unproven
cases. The data were compiled by time to diagnosis, visual
acuity, microbiology results, and additional factors, in
cluding patient demographics, incision site, intraocular
lens (IOL) material, surgeon experience, and surgical
complications.
Proven endophthalmitis was defined as any case present
ing with pain or loss of vision thought to be due to infection
and in which infection was proven by Gram stain, culture,
or polymerase chain reaction. Unproven or presumed
endophthalmitis was determined to be present when no test
yielded a positive result.
Data in the results presented here refer to the randomiza
tion protocol used in the ESCRS study.1 Group A, a control
group, received an intensive placebo drop regimen perioper
atively1; Group C received the active intensive perioperative
antibiotic drop regimen (levofloxacin 0.5%).1 In Group B, an
intracameral injection of cefuroxime 1 mg was added to the
regimen in Group A; in Group D, intracameral cefuroxime
1 mg was added to the regimen in Group C. All groups were
prescribed a standard postoperative antibiotic drop regimen
comprising topical levofloxacin 0.5%, 1 drop 4 times daily,
for at least 1 week to prevent wound infection. In all, approx
imately one half (8108) of the intent to treat patients received
an intracameral injection of cefuroxime 1 mg and one half
(8103) did not.
The endpoint of the study was the diagnosis of endoph
thalmitis. The subsequent management of individual
patients was at the discretion of the responsible surgeon.
No aspects of subsequent treatment were randomized, and
recording of the final visual outcome did not occur at a fixed
time point after diagnosis. Therefore, postoperative visual
acuities could not be subjected to statistical testing.
Statistical Analysis
Logistic regression analysis was performed to determine
whether any sign or symptom recorded for each patient
when he or she presented with endophthalmitis was more
frequently associated with proven or unproven cases. Each
factor was screened individually using univariable binary
logistic regression. All factors with a likelihood ratio test P
value of 0.20 or less were made available for final multivari
able logistic regression analyses. The likelihood ratio test sta
tistical significance of each factor is reported with its odds
ratio (OR) and associated 95% confidence interval (CI).
RESULTS
Of the 29 cases of endophthalmitis in the ESCRS study,
20 were proven and 9 were unproven. The median
time to presentation with signs and symptoms was
4.5 days (4.0 days if the 1 late-presenting case at 132
days is discounted) in proven cases and 9.0 days in
unproven cases; the median time overall was 5 days.
Table 1 shows the distribution of cases grouped by
time to onset; a greater proportion of proven cases
occurred within the first 7 days postoperatively.
Table 2 shows the visual acuity and the signs and
symptoms on presentation postoperatively. Table 3
shows the signs and symptoms by case and the results
of univariable logistic regression analysis, which
indicated that swollen lids and pain were the only
sign or symptom significantly associated with proven
cases.
After multivariable logistic regression modeling,
swollen lids (P .04; OR 18.29; 95% CI, 1.07-
311.42) and an opaque vitreous (P .05; OR
13.70; 95% CI, 1.06-177.16) were found to be signifi-
cantly associatedwith the proven cases of endophthal-
mitis. A review of cases that did not have pain, swollen
lids, or opaque vitreous, performed to determine
whether there were common factors, showed that 1
unmixed case of infection due to Propionibacterium
acnes was not associated with pain or swollen lids
but was associated with an opaque vitreous. All 8
cases caused by streptococcal infection were associ-
ated with pain, hypopyon, and chemotic conjunctiva
and with clear corneal incisions (Table 4). No com-
monality of microbial species with other factors was
evident among cases, with further analysis impractical
due to the small numbers involved.
Although postoperative visual acuities striking
were not statistically tested, there was a difference in
visual outcomes between cases of streptococcal and
cases of staphylococcal infections, with the outcomes
being far worse in streptococcal cases. The final visual
acuity range in staphylococcal infections (11 cases,
excluding 1 mixed case) was between 20/20 and 20/
80, with no patient being legally blind (ie, 20/200 or
worse); 3 of these cases received an intracameral cefur-
oxime injection. Conversely, the final visual acuity
range in streptococcal infections (8 cases) was between
20/20 and no light perception; 5 of these patients were
legally blind, all due to streptococci, and none of the 5
received intracameral cefuroxime (Table 4). All 8 cases
with streptococcal infection were in the groups that
did not receive intracameral cefuroxime.
Table 1. Time to onset of signs and symptoms in 29 cases of
endophthalmitis.
Cases
Days to Onset Total Proven Unproven
1 3 9 8 1
4 7 9 7 2
8 14 7 3 4
O14 4 2 2
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Table 4 shows the microorganisms isolated in the 20
cases of proven endophthalmitis, ordered by time to
onset of signs and symptoms as well as the data
from all 29 cases by treatment group, age, and sex. It
also shows the distribution of risk factors identified
as significant in the overall study results. These in-
clude site of incision, IOL opticmaterial, surgeon expe-
rience, and presence of surgical complications.
Of the 29 endophthalmitis cases, 8 proven cases and 1
unproven case presented within 1 to 3 days postopera-
tively; all 8 cases were in Group A or Group C, which
did not receive an intracameral injection of cefuroxime
(Table 4). There was no case of early-onset (1 to 3
days) endophthalmitis in the 2 groups that received
an intracameral cefuroxime injection. The early-onset
cases included 6 isolates of streptococcal species and 2
isolates of Staphylococcus epidermidis andwere generally
associated with rapid and severe onset of symptoms.
Of the endophthalmitis cases presenting from 4 to 7
days, 7 were proven and 2 were unproven. Five of the
7 proven cases occurred in the groups that did not
receive intracameral cefuroxime and 2 cases, in the
groups that received intracameral cefuroxime.
The 7 cases with an onset of 8 to 14 days included 3
proven and 4 unproven cases. Of the proven cases, 1
occurred in a cefuroxime-treated group (Group B); in
this case, S epidermidis was isolated and poor wound
healing was reported. Of the unproven cases, 1 was
in a cefuroxime-treated group and was associated
with an operative complication.
The 2 late-onset proven cases (O14 days) occurred
in control Group A, which did not receive cefuroxime,
and included 1 case of S epidermidis and 1 of Propioni-
bacterium species. Two late-onset unproven cases also
occurred, both in Group A.
DISCUSSION
We describe the signs, symptoms, and characteristics
of endophthalmitis cases in the largest series of pa-
tients evaluated for evidence-based prophylaxis of en-
dophthalmitis after cataract surgery in a randomized
clinical trial. Our data from the 16 211 intent-to-treat
patients were unique in the inclusion of a control
group to permit statistical evaluation of the specific
intervention; that is, intracameral injection of 1 mg
cefuroxime at the close of cataract surgery.
The report of the Endophthalmitis Vitrectomy Study
(EVS), which was conducted from 1990 to 1994, de-
scribes a comparable series of patients with postoper-
ative endophthalmitis.5 Many characteristics in the
EVS study align with findings in the ESCRS study
(Table 5). There were more patients in the EVS study
because all were presumed cases of endophthalmitis
referred for treatment within a study protocol; however,
prophylactic perioperative treatments varied, and re-
cruitment was limited to 6 weeks postoperatively.
The median time to diagnosis in the United States–
based EVS study and the European-based ESCRS
study was similar (6 days and 5 days, respectively);
the early-presenting patients in the control group are
the likely reason for the shorter time in the ESCRS
study. The majority of patients in both studies pre-
sented within 7 days after cataract surgery. In another
series that comprised culture-proven endophthalmitis
cases (73 eyes) only,6 the mean time to presentation
overall was 13 days (median 9 days); however, for
the 42% of patients who presented within 7 days after
cataract surgery, the mean time to presentation was 5
days. The somewhat longer time to presentation over-
all in that studywas associatedwith the use of the clear
corneal incision, whereas the EVS was associated with
the scleral incision technique. In the ESCRS study,
which used both surgical methods, 75% of proven en-
dophthalmitis cases presented within 7 days.
The frequency of patients presenting with pain,
swollen lids, and hypopyon is also comparable, al-
though the EVS study did not analyze differences in
signs and symptoms between proven cases and un-
proven cases. In the ESCRS study, hypopyon was
present in 80% of proven cases and 56% of unproven
cases, resulting in an overall incidence of 72%.
The percentage of culture-proven cases (69%) was
identical in both studies and aligned with the 62%
culture-positive cases described in an Asian report.7
The frequency of total gram-positive microorganisms
was almost identical (63% versus 62%) in the 2
studies, although streptococci were encountered
more frequently in the ESCRS study. Streptococcal
endophthalmitis resulted in earlier onset and notably
worse outcomes than infection by staphylococcal spe-
cies, a trend also reflected in EVS results and else-
where.8–10 In a series by Lalwani et al.,6 Streptococcus
species were identified in 8.2% of isolates overall,
with most (83.3%) occurring in the early-presenting
group. In the ESCRS study, 75.0% (6/8) of streptococ-
cal cases presented within 3 days and 100% within 7
days. None of the eyes in the ESCRS study with the
worst visual outcomes after streptococcal infection re-
ceived intracameral cefuroxime. This indicates that the
cefuroxime injection was an important factor in pro-
tecting patients against the development of postopera-
tive streptococcal endophthalmitis with its associated
destructive sequelae, which often result in a poor
visual outcome. These cases of streptococcal infection
reemphasize the importance of this pathogen in the
etiology of postoperative endophthalmitis and sug-
gest that proposed regimens for prophylaxis of en-
dophthalmitis ensure microbiologic efficacy against
this class of microbes.
Five cases of endophthalmitis (3 proven, 2 un-
proven) occurred in the ESCRS study groups that re-
ceived an intracameral cefuroxime injection. One
unproven case involved an intraoperative complica-
tion. In another series,11 approximately one half of
the endophthalmitis cases were also associated with
intraoperative complications. One proven case in a
cefuroxime-treated group, which presented 13 days
postoperatively, was associated with poor wound ap-
position. This occurred in a patient whose occupation
was hospital based, raising the possibility that a postop-
erative nosocomial infection with a less susceptible
strain of S epidermidis occurred at the wound site. The
isolate was termed resistant to cefuroxime by previous
definitions.4 Another isolate in the cefuroxime-treated
groups was identified as Staphylococcus warneri in
a patient presenting 4 days after surgery with visual
acuity worse than 6/60, swollen lids, and corneal
edema, but no hypopyon or vitreous condensation.
This isolate was lost to sensitivity testing for cefurox-
ime, although culture results indicated susceptibility
to several antibiotics, including methicillin, but resis-
tance to penicillin and gentamicin. Ocular isolates of
S warneri are described in the literature, identified
from corneal/external eye infections in patients with
chronic blepharitis, purulent conjunctivitis, and sup-
purative keratitis12 and in hospitals, neonatal units,
and food.13–15 The third isolate in cefuroxime-treated
groups was S epidermidis, determined to be sensitive
to cefuroxime.
Table 2. Signs and symptoms on presentation associated with the endophthalmitis cases.
Sign or Symptom
Case
Type/# VA
Corneal
Edema Hypopyon Opaque Vit
Vit
Condensation
Chemotic
Conj
Proven
28 !20/200 U U U N U
10 20/200 U U U d U
22 !20/200 U U U U U
21 20/40 U U d d U
27 !20/200 U U U U U
9 !20/200 d U U U U
14 !20/200 U U U U U
3 20/40 d U d N U
17 !20/200 U U U N d
4* !20/200 U d d d U
12* !20/200 U U U N d
6 20/60 U U U U U
2 !20/200 U U U d U
25 !20/200 U U U U d
18 !20/200 U U N N d
5 20/200 U d N d U
24 20/200 U U U U U
8* !20/200 U U d d d
20 20/120 U d d U d
29 20/80 d d U U d
Nonproven d d
16 20/80 U U d d U
15* 20/200 U d d U U
19 20/200 U d d U d
1* 20/200 U U d U U
11 !20/200 d d U d d
13 !20/200 U U d d d
26 !20/200 d U U d d
7 !20/200 U U N N d
23 !20/200 U d N U d
UZ sign/symptom present;dZ sign/symptom not present; ConjZ conjunctiva; NZ presence or absence of sign/symptom not
documented; Pupil MembZ pupillary membrane; VAZ visual acuity; VitZ vitreous
*Patient received intracameral cefuroxime at close of surgery
Two cases of unproven endophthalmitis occurred in
the cefuroxime-treated groups; an intraoperative
complication was associated with 1 of the cases. Intra-
operative complications were also associated with
culture-negative cases in another series16 in which en-
dophthalmitis occurred after a variety of surgical
procedures.
In the intent-to-treat patient population that re-
ceived intracameral cefuroxime (Group B and Group
D), the rate of total endophthalmitis was 0.062%. The
rate in patients who did not receive cefuroxime (Group
A and Group C) was approximately 5 times higher
(0.296%). The baseline rates in ESCRS study groups
not receiving cefuroxime may be compared with
presumed postoperative endophthalmitis rates
(0.215%,17 0.265%,18 0.286% and at times 0.330%19)
in studies that included patient populations in referral
centers or older patients or with rates associated with
changing trends in surgical technique. Despite
changes in surgical techniques and an increasingly
elderly population, the rate of endophthalmitis after
cataract surgery remained near 0.2% in a Western
Australia study that spanned almost 2 decades.20
These series presumably incorporated some form of
perioperative prophylaxis and did not include control
groups. A more contemporary analysis21 found
a 0.35% rate of postoperative endophthalmitis in
a group of patients who did not receive intracameral
cefuroxime. This is an especially relevant comparison
to the ESCRS findings because topical antibiotic
Sign or Symptom
Pupil
Memb
Swollen
Lid
View of
Fundus
View
of Retinal
Vessels
Loss
of Red
Reflex
Blurred
Vision
Loss
of Vision Pain Other
d U d d U N U U d
U U U U U U U U
d d d d U U U U d
U U U U d U U U d
d U d d d U U U d
U U d d d U U U d
d U d d d U U U d
U N U U d d d U U
d d d d d U U U d
U U U U d U U U d
U U d d N U U U d
U U U U d U d U d
U U d d U U U U d
d d d d U U U U d
U d d d U U U U d
U U U d d U U U d
d d d d d U U U d
d U d d d U U d d
d d U U d U d U d
U U U d U U d d
U d d d d U U d d
d U U U d U U U d
U d U U d U N d d
d d N N U U U U U
d d d U d U U d d
U d d d d U U d d
d d d d d U U d d
N d N N N U U U d
d d d d U U U U d
Table 2. (Cont.)
ointment or drops were not routinely used at those
centers.
Such reports underscore the value of the ESCRS
study results in answering the call for randomized
trials to contribute statistically valid data for strategies
to reduce endophthalmitis rates as patient numbers
increase worldwide.17 In particular, because reported
rates of anterior chamber contamination during cata-
ract surgery are extraordinarily high (20% to 24%,22
29%,23 43%24), it should not be surprising to find base-
line endophthalmitis rates in ESCRS control groups
that reflect the higher range of reported rates. The
lower endophthalmitis rates in cefuroxime-treated
groups parallel those in other series in the literature;
however, without predefined study protocols to ad-
dress the significance of specific interventions, assump-
tions outside the ESCRS study remain speculative and
clouded by themany factors at play in various surgical
settings.
To date, intracameral cefuroxime remains the only
prophylactic intervention proven to reduce rates of en-
dophthalmitis after cataract surgery. Although fourth-
generation fluoroquinolones have been promoted as
a potential substitute for intracameral cefuroxime, re-
cent reports describing steadily increasing resistance
of endophthalmitis isolates to fourth-generation fluo-
roquinolones ring a cautionary note. From 1990 to
2004, in 111 ocular endophthalmitis isolates of coagu-
lase-negative Staphylococcus (CNS), 67.6% being S
epidermidis, the percentage of strains sensitive to moxi-
floxacin declined significantly from 96.6% (1990 to
1994) to 65.4% (2000 to 2004) (P .03), a 32.2% decline
over a relatively short period.25
A significant increase in the prevalence of resistant
isolates was also documented for moxifloxacin over
this time period (P .007). The minimum inhibitory
concentration required to inhibit the growth of 90%
of organisms for moxifloxacin increased by a factor
of 266, rising from 0.12 mg/mL (93.2% of isolates) dur-
ing 1990 to 1994, to 4.00 mg/mL (100% of isolates) dur-
ing 1995 to 1999, and to 32.00 mg/mL (100% of isolates)
during 2000 to 2004. Overall, only 72.1% of the 111
CNS isolates recovered from patients with clinical en-
dophthalmitis were considered sensitive to moxifloxa-
cin (%0.5 mg/mL).25
In the ESCRS study, 2 to 3 of the 5 S epidermidis iso-
lates tested showed reduced susceptibility tomoxiflox-
acin.4 This trend, together with reports describing
postoperative endophthalmitis despite perioperative
and postoperative use of fourth-generation fluoroqui-
nolone drops,26 the potentially unresolved questions
of safe dosage27 and cautionary statements that
eyedrops such as moxifloxacin should not be injected
directly into the eye (Alcon Laboratories, Vigamox
product insert), suggest that further large-scale ran-
domized trials are required to validate any substitu-
tions of cefuroxime for intracameral injection at this
time.
Table 3. Presence or absence of each sign and symptom and results of univariable logistic regression analysis.
Percentage† Univariable Logistic Regression
Parameter Proven Cases Unproven Cases P Value OR 95% CI
Sign
VA 20/200 or worse 75 89 .41 0.38 0.04 3.79
Corneal edema 85 78 .64 1.62 0.22 11.89
Hypopyon 80 56 .18 3.20 0.58 17.72
Vitreous opaque 72 29 .06 6.50 0.94 45.11
Vitreous condensation 60 50 .65 1.50 0.27 8.45
Chemotic conjunctiva 65 33 .12 3.71 0.70 19.59
Pupillary membrane 55 38 .41 2.04 0.38 10.94
Swollen lids 63 11 .02 13.71 1.41 133.85
View of fundus 40 29 .59 1.67 0.26 10.79
View of retinal vessels 35 43 .71 0.72 0.12 4.16
Loss of red reflex 32 25 .73 1.38 0.21 8.98
Symptom
Blurring of vision* 89 100 d d d
Loss of vision* 85 100 d d d
Pain 90 56 .05 7.20 1.01 51.39
Other 10 11 .93 0.89 0.07 11.28
CIZ confidence interval; ORZ odds ratio; VAZ visual acuity
*Data unsuitable for logistic regression
†Percentage based on cases in which presence/absence documented
Formulated and manufactured as an injectable, ce-
furoxime meets safety standards for drugs intended
for injection rather than topical use. The safety of intra-
cameral cefuroxime is supported in large numbers of
patients28,29 as well as by optical coherence tomogra-
phy after a 1 mg dose, after which no significant effect
on postoperative macular thickness was found.30
In conclusion, comparison of the signs and symp-
toms in cases of proven and unproven postoperative
endophthalmitis in theESCRS study showed that swol-
len lids, pain, and opaque vitreouswere statistically as-
sociated with the proven cases. Many characteristics of
the ESCRS studyparallel those of the EVS study and re-
ports from other regions. Five endophthalmitis cases
(3 proven, 2 unproven) occurred in cefuroxime-treated
groups; 1 of these was associated with poor wound
healing and another, with an intraoperative complica-
tion, similar to findings in other reported series. The
rates of endophthalmitis in ESCRS study groups paral-
lel those in a spectrum of reports that reflect the variety
of surgical settings and patient populations described
in the literature worldwide. The ESCRS study groups
that received an intracameral injection of cefuroxime
had a near 5-fold reduction in postoperative endoph-
thalmitis. Intracameral cefuroxime remains the only
prophylactic intervention to date with an evidence-
based benefit in the reduction of endophthalmitis after
cataract surgery.
Table 4. Description of proven and nonproven endophthalmitis cases.
Case
Type/#
Days to
Onset Organism
Tx
Group
Sex/Age
(Y) Incision Site
IOL Optic
Material
Surgeon
Experience
(# of Surgeries)
Surgical
Complications
Visual
Outcome†
Proven
28 1 Streptococcus salivarius C M/70 Clear corneal Silicone O500 No 20/60
10 2 Streptococcus pneumoniae A M/79 Clear corneal Silicone O500 No !20/200
22 2 Streptococcus pneumoniae A M/75 Clear corneal Silicone O500 No !20/200
21 2 Streptococcus salivarius A F/69 Clear corneal Acrylic O500 No !20/200
27 2 Streptococcus sanguis C M/78 Clear corneal Acrylic O500 No !20/200
9 3 Staphylococcus epidermidis C F/81 Scleral tunnel Silicone !100 No 20/25
14 3 Staphylococcus epidermidis A M/62 Clear corneal Acrylic O500 Yes 20/25
3 3 Streptococcus oralis C F/66 Clear corneal Acrylic O500 No 20/200
17 4 Staphylococcus epidermidis A F/79 Clear corneal Silicone O500 No 20/30
4* 4 Staphylococcus warneri D F/63 Clear corneal Acrylic 100 500 No 20/80
12* 5 Staphylococcus epidermidis B M/81 Clear corneal Acrylic O500 No 20/80
6 5 Staphylococcus epidermidis/
Streptococcus mitis
A M/67 Clear corneal Silicone O500 No 20/20
2 5 Streptococcus suis A M/68 Clear corneal Acrylic O500 Yes 20/30
25 7 Staphylococcus epidermidis C M/91 Clear corneal Acrylic O500 No 20/25
18 7 Staphylococcus hominis
or haemolyticus
C M/83 Clear corneal Silicone O500 No 20/40
5 8 Staphylococcus aureus/
Propionibacterium acnes
A M/71 Clear corneal Acrylic O500 No 20/30
24 10 Staphylococcus aureus C M/69 Clear corneal Acrylic O500 No 20/60
8* 13 Staphylococcus epidermidis B M/73 Clear corneal Silicone O500 No 20/25
20 16 Staphylococcus epidermidis A F/69 Clear corneal Silicone O500 No 20/20
29 132 Propionibacterium acnes A F/68 Clear corneal Silicone O500 No 20/20
Nonproven
16 3 d C M/71 Scleral tunnel Silicone 100 500 No 20/40
15* 4 d D F/72 Clear corneal Acrylic O500 No 20/25
19 4 d C F/78 Clear corneal Acrylic !100 No 20/30
1* 9 d B F/82 Clear corneal Silicone O500 Yes 20/60
11 9 d A F/74 Clear corneal Silicone 100 500 Yes 20/25
13 9 d C F/76 Clear corneal Acrylic O500 No 20/40
26 11 d A F/83 Clear corneal Acrylic O500 No 20/20
7 15 d A M/76 Clear corneal Acrylic O500 No 20/30
23 36 d A M/85 Clear corneal Acrylic O500 No 20/80
TxZ treatment
*Patient received intracameral cefuroxime at close of surgery (Groups B and D)
†Time between presentation and final visual acuity readings: range 3 weeks to 8 months
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